MiRNA-548ah, a Potential Molecule Associated with Transition from Immune Tolerance to Immune Activation of Chronic Hepatitis B

Overview

Journal Int J Mol Sci

Publisher MDPI

Specialties Biochemistry
Chemistry
Molecular Biology

Date 2014 Sep 9

PMID 25196343

Citations 18

Authors

Tong-Jing Xing

Hong-Tao Xu

Wen-Qing Yu

Bian Wang

Jing Zhang

Affiliations

Soon will be listed here.

Abstract

Objective: The present study aims to identify the differently expressed microRNA (miRNA) molecules and target genes of miRNA in the immune tolerance (IT) and immune activation (IA) stages of chronic hepatitis B (CHB).

Methods: miRNA expression profiles of peripheral blood mononuclear cells (PBMCs) at the IT and IA stages of CHB were screened using miRNA microarrays and authenticated using a quantitative real-time polymerase chain reaction (RT-PCR). Gene ontology (GO) and the Kyoto encyclopedia of genes and genomes (KEGG) were used to analyze the significant functions and pathways of possible target genes of miRNAs. Assays of the gain and loss of function of the miRNAs were performed to verify the target genes in THP-1 cell lines. The luciferase reporter test was used on 293T cells as direct targets.

Results: Significantly upregulated miR-548 and miR-4804 were observed in the miRNA microarrays and confirmed by RT-PCR in PBMCs at the IT and IA stages of CHB. GO and KEGG analysis revealed that MiR-548 and miR-4804 could be involved in numerous signaling pathways and protein binding activity. IFNγR1 was predicted as a target gene and validated as the direct gene of MiR-548. Significant negative correlation was found between the miR-548ah and mRNA levels of IFN-γR1 in CHB patients.

Conclusions: The abnormal expression profiles of miRNA in PBMCs could be closely associated with immune activation of chronic HBV infection. miR-548, by targeting IFN-γR1, may represent a mechanism that can facilitate viral pathogenesis and help determine new therapeutic molecular targets.

Citing Articles

Therapeutic Implication of miRNAs as an Active Regulatory Player in the Management of Pain: A Review.

Hassan M, Shahzadi S, Yasir M, Chun W, Kloczkowski A Genes (Basel). 2024; 15(8).

PMID: 39202362 PMC: 11353898. DOI: 10.3390/genes15081003.

Is liver biopsy essential to identifying the immune tolerant phase of chronic hepatitis B?.

Oh J, Sinn D Clin Mol Hepatol. 2023; 29(2):367-370.

PMID: 36935649 PMC: 10121279. DOI: 10.3350/cmh.2023.0054.

Single cell gene expression profiling of nasal ciliated cells reveals distinctive biological processes related to epigenetic mechanisms in patients with severe COVID-19.

Diambra L, Alonso A, Sookoian S, Pirola C Comput Biol Med. 2022; 148:105895.

PMID: 35926268 PMC: 9338837. DOI: 10.1016/j.compbiomed.2022.105895.

Differences Between Sorafenib and Lenvatinib Treatment from Genetic and Clinical Perspectives for Patients with Hepatocellular Carcinoma.

Wang L, Xiao B, Cui M, Zhang B Med Sci Monit. 2022; 28:e934936.

PMID: 35473892 PMC: 9059551. DOI: 10.12659/MSM.934936.

miR-548d-3p Is Up-Regulated in Human Visceral Leishmaniasis and Suppresses Parasite Growth in Macrophages.

Ramos-Sanchez E, Reis L, Souza M, Muxel S, Santos K, Lagos D Front Cell Infect Microbiol. 2022; 12():826039.

PMID: 35265535 PMC: 8900537. DOI: 10.3389/fcimb.2022.826039.

References

Jiang X, Kanda T, Wu S, Nakamura M, Miyamura T, Nakamoto S . Regulation of microRNA by hepatitis B virus infection and their possible association with control of innate immunity. World J Gastroenterol. 2014; 20(23):7197-206. PMC: 4064064. DOI: 10.3748/wjg.v20.i23.7197. View

Nordmann Winther T, Bang-Berthelsen C, Heiberg I, Pociot F, Hogh B . Differential plasma microRNA profiles in HBeAg positive and HBeAg negative children with chronic hepatitis B. PLoS One. 2013; 8(3):e58236. PMC: 3587589. DOI: 10.1371/journal.pone.0058236. View

Lu L, Boldin M, Chaudhry A, Lin L, Taganov K, Hanada T . Function of miR-146a in controlling Treg cell-mediated regulation of Th1 responses. Cell. 2010; 142(6):914-29. PMC: 3049116. DOI: 10.1016/j.cell.2010.08.012. View

Li Y, Xie J, Xu X, Wang J, Ao F, Wan Y . MicroRNA-548 down-regulates host antiviral response via direct targeting of IFN-λ1. Protein Cell. 2012; 4(2):130-41. PMC: 4875363. DOI: 10.1007/s13238-012-2081-y. View

Ait-Goughoulte M, Lucifora J, Zoulim F, Durantel D . Innate antiviral immune responses to hepatitis B virus. Viruses. 2011; 2(7):1394-1410. PMC: 3185716. DOI: 10.3390/v2071394. View

Tsai H, Tsai T, Lu T, Yang C . Immunopathology of hepatitis B virus infection. Int Rev Immunol. 2008; 27(6):427-46. DOI: 10.1080/08830180802295757. View

Lok A, McMahon B . Chronic hepatitis B. Hepatology. 2007; 45(2):507-39. DOI: 10.1002/hep.21513. View

Das A, Maini M . Innate and adaptive immune responses in hepatitis B virus infection. Dig Dis. 2010; 28(1):126-32. DOI: 10.1159/000282075. View

Contreras J, Rao D . MicroRNAs in inflammation and immune responses. Leukemia. 2011; 26(3):404-13. DOI: 10.1038/leu.2011.356. View

10.

Li Q, Chau J, Ebert P, Sylvester G, Min H, Liu G . miR-181a is an intrinsic modulator of T cell sensitivity and selection. Cell. 2007; 129(1):147-61. DOI: 10.1016/j.cell.2007.03.008. View

11.

Dykxhoorn D, Lieberman J . The silent revolution: RNA interference as basic biology, research tool, and therapeutic. Annu Rev Med. 2005; 56:401-23. DOI: 10.1146/annurev.med.56.082103.104606. View

12.

Maini M, Schurich A . The molecular basis of the failed immune response in chronic HBV: therapeutic implications. J Hepatol. 2010; 52(4):616-9. DOI: 10.1016/j.jhep.2009.12.017. View

13.

Wang S, Qiu L, Yan X, Jin W, Wang Y, Chen L . Loss of microRNA 122 expression in patients with hepatitis B enhances hepatitis B virus replication through cyclin G(1) -modulated P53 activity. Hepatology. 2011; 55(3):730-41. DOI: 10.1002/hep.24809. View

14.

Esau C, Monia B . Therapeutic potential for microRNAs. Adv Drug Deliv Rev. 2007; 59(2-3):101-14. DOI: 10.1016/j.addr.2007.03.007. View

15.

Lee W . Hepatitis B virus infection. N Engl J Med. 1997; 337(24):1733-45. DOI: 10.1056/NEJM199712113372406. View

16.

Dai R, Ahmed S . MicroRNA, a new paradigm for understanding immunoregulation, inflammation, and autoimmune diseases. Transl Res. 2011; 157(4):163-79. PMC: 3072681. DOI: 10.1016/j.trsl.2011.01.007. View

17.

Revill P, Yuan Z . New insights into how HBV manipulates the innate immune response to establish acute and persistent infection. Antivir Ther. 2013; 18(1):1-15. DOI: 10.3851/IMP2542. View

18.

Chen L, Li C, Peng Z, Zhao J, Gong G, Tan D . miR-197 Expression in Peripheral Blood Mononuclear Cells from Hepatitis B Virus-Infected Patients. Gut Liver. 2013; 7(3):335-42. PMC: 3661967. DOI: 10.5009/gnl.2013.7.3.335. View

19.

Liang T, Guo L, Liu C . Genome-wide analysis of mir-548 gene family reveals evolutionary and functional implications. J Biomed Biotechnol. 2012; 2012:679563. PMC: 3468316. DOI: 10.1155/2012/679563. View

20.

Pan X, Ma H, Jin Q, Wei L . Characterization of microRNA expression profiles associated with hepatitis B virus replication and clearance in vivo and in vitro. J Gastroenterol Hepatol. 2011; 27(4):805-12. DOI: 10.1111/j.1440-1746.2011.06979.x. View